ドルテグラビルおよび併用薬の世界市場:規模・現状・予測2019-2025

【英語タイトル】Global Dolutegravir and Its Combination Drug Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料(QYR20FB07925)・商品コード:QYR20FB07925
・発行会社(調査会社):QYResearch
・発行日:2019年11月(※2024年版があります。お問い合わせください)
・ページ数:97
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※当調査レポートでは、ドルテグラビルおよび併用薬の世界市場について調査・分析し、ドルテグラビルおよび併用薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別(ドルテグラビル、アバカビル/ドルテグラビル/ラミブジン、ドルテグラビル/リルピビリン)、用途別(病院、診療所、医薬品センター、その他)、地域別(北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米)に区分して市場規模を算出しました。


・レポートの概要
・世界のドルテグラビルおよび併用薬市場動向
・主要企業別マーケットシェア
・ドルテグラビルおよび併用薬の種類別市場規模2014-2019
(ドルテグラビル、アバカビル/ドルテグラビル/ラミブジン、ドルテグラビル/リルピビリン)
・ドルテグラビルおよび併用薬の用途別市場規模2014-2019
(病院、診療所、医薬品センター、その他)
・ドルテグラビルおよび併用薬の北米市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬のヨーロッパ市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬の中国市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬の日本国内市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬の東南アジア市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬のインド市場:主要企業・種類別/用途別市場規模
・ドルテグラビルおよび併用薬の中南米市場:主要企業・種類別/用途別市場規模
・主要企業のプロフィール
(ViiV Healthcare (GSK)、Adcock Ingram Limited、Aurobindo Pharma、Cipla、Emcure Pharmaceuticals、LAURUS Labs、Mylan、Ranbaxy Pharmaceuticals、Shanghai Desano Pharmaceuticals、JNJ)
・ドルテグラビルおよび併用薬の市場規模予測2019-2025
(種類別、用途別、地域別市場予測)
・アナリストの観点・結論
...
【レポートの概要】

In 2018, the global Dolutegravir and Its Combination Drug market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Dolutegravir and Its Combination Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Dolutegravir and Its Combination Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
ViiV Healthcare (GSK)
Adcock Ingram Limited
Aurobindo Pharma
Cipla
Emcure Pharmaceuticals
LAURUS Labs
Mylan
Ranbaxy Pharmaceuticals
Shanghai Desano Pharmaceuticals
JNJ

Market segment by Type, the product can be split into
Dolutegravir
Abacavir/Dolutegravir/Lamivudine
Dolutegravir/Rilpivirine

Market segment by Application, split into
Hospital
Clinic
Drug Center
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Dolutegravir and Its Combination Drug status, future forecast, growth opportunity, key market and key players.
To present the Dolutegravir and Its Combination Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Dolutegravir and Its Combination Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Dolutegravir and Its Combination Drug Market Size Growth Rate by Type (2014-2025)
1.4.2 Dolutegravir
1.4.3 Abacavir/Dolutegravir/Lamivudine
1.4.4 Dolutegravir/Rilpivirine
1.5 Market by Application
1.5.1 Global Dolutegravir and Its Combination Drug Market Share by Application (2019-2025)
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Dolutegravir and Its Combination Drug Market Size
2.2 Dolutegravir and Its Combination Drug Growth Trends by Regions
2.2.1 Dolutegravir and Its Combination Drug Market Size by Regions (2019-2025)
2.2.2 Dolutegravir and Its Combination Drug Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Dolutegravir and Its Combination Drug Market Size by by Players
3.1.1 Global Dolutegravir and Its Combination Drug Revenue by by Players (2014-2019)
3.1.2 Global Dolutegravir and Its Combination Drug Revenue Market Share by by Players (2014-2019)
3.1.3 Global Dolutegravir and Its Combination Drug Market Concentration Ratio (CR5 and HHI)
3.2 Dolutegravir and Its Combination Drug Key Players Head office and Area Served
3.3 Key Players Dolutegravir and Its Combination Drug Product/Solution/Service
3.4 Date of Enter into Dolutegravir and Its Combination Drug Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Dolutegravir and Its Combination Drug Market Size by Type (2014-2019)
4.2 Global Dolutegravir and Its Combination Drug Market Size by Application (2014-2019)

5 North America
5.1 North America Dolutegravir and Its Combination Drug Market Size (2014-2019)
5.2 Dolutegravir and Its Combination Drug Key Players in North America
5.3 North America Dolutegravir and Its Combination Drug Market Size by Type
5.4 North America Dolutegravir and Its Combination Drug Market Size by Application

6 Europe
6.1 Europe Dolutegravir and Its Combination Drug Market Size (2014-2019)
6.2 Dolutegravir and Its Combination Drug Key Players in Europe
6.3 Europe Dolutegravir and Its Combination Drug Market Size by Type
6.4 Europe Dolutegravir and Its Combination Drug Market Size by Application

7 China
7.1 China Dolutegravir and Its Combination Drug Market Size (2014-2019)
7.2 Dolutegravir and Its Combination Drug Key Players in China
7.3 China Dolutegravir and Its Combination Drug Market Size by Type
7.4 China Dolutegravir and Its Combination Drug Market Size by Application

8 Japan
8.1 Japan Dolutegravir and Its Combination Drug Market Size (2014-2019)
8.2 Dolutegravir and Its Combination Drug Key Players in Japan
8.3 Japan Dolutegravir and Its Combination Drug Market Size by Type
8.4 Japan Dolutegravir and Its Combination Drug Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Dolutegravir and Its Combination Drug Market Size (2014-2019)
9.2 Dolutegravir and Its Combination Drug Key Players in Southeast Asia
9.3 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Type
9.4 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Application

10 India
10.1 India Dolutegravir and Its Combination Drug Market Size (2014-2019)
10.2 Dolutegravir and Its Combination Drug Key Players in India
10.3 India Dolutegravir and Its Combination Drug Market Size by Type
10.4 India Dolutegravir and Its Combination Drug Market Size by Application

11 Central & South America
11.1 Central & South America Dolutegravir and Its Combination Drug Market Size (2014-2019)
11.2 Dolutegravir and Its Combination Drug Key Players in Central & South America
11.3 Central & South America Dolutegravir and Its Combination Drug Market Size by Type
11.4 Central & South America Dolutegravir and Its Combination Drug Market Size by Application

12 International Players Profiles
12.1 ViiV Healthcare (GSK)
12.1.1 ViiV Healthcare (GSK) Company Details
12.1.2 Company Description and Business Overview
12.1.3 Dolutegravir and Its Combination Drug Introduction
12.1.4 ViiV Healthcare (GSK) Revenue in Dolutegravir and Its Combination Drug Business (2014-2019))
12.1.5 ViiV Healthcare (GSK) Recent Development
12.2 Adcock Ingram Limited
12.2.1 Adcock Ingram Limited Company Details
12.2.2 Company Description and Business Overview
12.2.3 Dolutegravir and Its Combination Drug Introduction
12.2.4 Adcock Ingram Limited Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.2.5 Adcock Ingram Limited Recent Development
12.3 Aurobindo Pharma
12.3.1 Aurobindo Pharma Company Details
12.3.2 Company Description and Business Overview
12.3.3 Dolutegravir and Its Combination Drug Introduction
12.3.4 Aurobindo Pharma Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.3.5 Aurobindo Pharma Recent Development
12.4 Cipla
12.4.1 Cipla Company Details
12.4.2 Company Description and Business Overview
12.4.3 Dolutegravir and Its Combination Drug Introduction
12.4.4 Cipla Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.4.5 Cipla Recent Development
12.5 Emcure Pharmaceuticals
12.5.1 Emcure Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Dolutegravir and Its Combination Drug Introduction
12.5.4 Emcure Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.5.5 Emcure Pharmaceuticals Recent Development
12.6 LAURUS Labs
12.6.1 LAURUS Labs Company Details
12.6.2 Company Description and Business Overview
12.6.3 Dolutegravir and Its Combination Drug Introduction
12.6.4 LAURUS Labs Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.6.5 LAURUS Labs Recent Development
12.7 Mylan
12.7.1 Mylan Company Details
12.7.2 Company Description and Business Overview
12.7.3 Dolutegravir and Its Combination Drug Introduction
12.7.4 Mylan Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.7.5 Mylan Recent Development
12.8 Ranbaxy Pharmaceuticals
12.8.1 Ranbaxy Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Dolutegravir and Its Combination Drug Introduction
12.8.4 Ranbaxy Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.8.5 Ranbaxy Pharmaceuticals Recent Development
12.9 Shanghai Desano Pharmaceuticals
12.9.1 Shanghai Desano Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Dolutegravir and Its Combination Drug Introduction
12.9.4 Shanghai Desano Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.9.5 Shanghai Desano Pharmaceuticals Recent Development
12.10 JNJ
12.10.1 JNJ Company Details
12.10.2 Company Description and Business Overview
12.10.3 Dolutegravir and Its Combination Drug Introduction
12.10.4 JNJ Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.10.5 JNJ Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details



【掲載企業】

ViiV Healthcare (GSK)、Adcock Ingram Limited、Aurobindo Pharma、Cipla、Emcure Pharmaceuticals、LAURUS Labs、Mylan、Ranbaxy Pharmaceuticals、Shanghai Desano Pharmaceuticals、JNJ

★調査レポート[ドルテグラビルおよび併用薬の世界市場:規模・現状・予測2019-2025] (コード:QYR20FB07925)販売に関する免責事項を必ずご確認ください。
★調査レポート[ドルテグラビルおよび併用薬の世界市場:規模・現状・予測2019-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆